BRAF and melanoma: Thus, combining T-VEC and BRAF/MEK inhibition might represent a potentially promising avenue to enhance T-VEC efficacy in BRAF-mutated and BRAF-wildtype melanoma and requires further pre-clinical and clinical validation.